Danaher is making good use of mergers and acquisitions once again. But we could have had enough
Danaher's days in the portfolio may be numbered. We were once again disappointed after Danaher's latest acquisition plan failed to…
Jim Cramer
Danaher Stock Fails to Rise on Strong Earnings, Leaving Us to Wonder What's Next
Danaher shares fell Wednesday as Wall Street failed to give the supplier of tools and equipment to drugmakers and hospitals…
Another Alliance Between Healthcare and AI Indicates Why Pharma Stocks Could Make a Comeback
Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating the early detection of lung cancer marks the latest way…
Eli Lilly investors shouldn't worry that rival Novo Nordisk has the first anti-obesity pill on sale
Jim Cramer says not to worry about Novo Nordisk's lead over Club that has Eli Lilly in the obesity pill…
Why Wall Street and Jim Cramer Think Danaher Stock Is 'Ready to Play'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
Jim Cramer has faith in Danaher's turnaround as life sciences come back to life
Life sciences stocks are experiencing a resurgence, and that's good news for Danaher. Connecting the dots with better times ahead…
We're raising our Eli Lilly price target – what a difference a quarter makes!
Eli Lilly shares rose Thursday after the drugmaker posted a strong third quarter, boosted by sales of its popular GLP-1…
We're downgrading it, considering the next step
Shares of Abbott Laboratories fell 3% on Wednesday after the diversified healthcare company turned in another less-than-stellar quarter. Revenue in…
We are buying the sauce in a stock and health science stock that has been reduced enough
We are buying 20 more Danaher shares at approximately $ 180 each. After Thursday's trade, Jim Cramer's charitable trust will…
Jim Cramer says that Eli Lilly's obesity pill could be more a “drug for life” than the shots
Do not count Eli Lilly's oral medication for obesity and diabetes yet, according to Jim Cramer de CNBC. That was…